> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rainer Blair Lines Up 71,963 Danaher Shares For A Planned $16.9 Million Sale
- URL: https://www.bullished.co/rainer-blair-lines-up-71-963-danaher-shares-for-a-planned-16-9-million-sale-14b44de3/
- Published: 2026-11-09T22:17:49.000Z
- Updated: 2026-11-09T22:17:49.000Z
- Description: Fidelity Brokerage Services would handle the proposed transaction, which covers shares from restricted-stock vesting and an option grant.
- Author: Matteo Parrino
- Tags: Insider Trades, DHR, Industry: Healthcare

Rainer Blair plans to sell [$16.9 million](https://www.sec.gov/Archives/edgar/data/0001692177/000195917326007885/xsl144X01/primary%5Fdoc.xml?ref=bullished.co) in shares of [Danaher](https://www.bullished.co/tag/dhr/), which supplies instruments, consumables, software and services for biotechnology, life sciences and diagnostics. The proposed transaction covers 71,963 shares, according to a notice of a planned sale filed with the SEC Monday.

## Fidelity Would Handle The Sale

Blair listed Fidelity Brokerage Services as the broker and Monday as the approximate sale date. The $16.9 million is the notice's aggregate market value for the shares, rather than proceeds from a completed sale.

The stock comes from [restricted-stock vesting](https://www.sec.gov/Archives/edgar/data/0001692177/000195917326007885/xsl144X01/primary%5Fdoc.xml?ref=bullished.co) on February 2, 2026, received as compensation, and an option grant dated Monday with payment in cash.

## A Modest Gain Since Year-End

DHR shares had gained 0.6% this year through Friday's close. Over the past 12 months through Friday's close, the gain was about 9%, placing Blair's proposed sale against a larger advance over that longer period.

Danaher's biotechnology business supplies drug-development and manufacturing equipment and consumables through brands including Cytiva and Pall. Its life-sciences operations sell research instruments, including microscopes and mass spectrometers, while its diagnostics business supplies testing tools used by hospitals, physicians' offices and reference laboratories.

The company has more than 15 operating businesses and facilities in approximately 50 countries. The United States accounted for 41% of sales in 2025.

Blair's notice records an intended sale; it does not establish that the shares have been sold.

### Sources

- [Form 144 — Rainer Blair (DHR)](https://www.sec.gov/Archives/edgar/data/0001692177/000195917326007885/xsl144X01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR

### More on Danaher

- [Fidelity Parent FMR Holds 5.6% Of Danaher, Certifies It Isn't Seeking Control](https://www.bullished.co/fidelity-parent-fmr-holds-5-6-of-danaher-certifies-it-isnt-seeking-control-a2d4041c/)
- [Danaher's New CEO Says Growth Fell Short Of Portfolio's 'Full Potential' And Names Share Gain Her 'Report Card'](https://www.bullished.co/danahers-new-ceo-says-growth-fell-short-of-portfolios-full-potential-and-names-share-gain-ab8ddb5f/)
- [Danaher's Tax Line Swung To A $75 Million Benefit As Diagnostics Margin Fell To 21.3%](https://www.bullished.co/danahers-tax-line-swung-to-a-75-million-benefit-as-diagnostics-margin-fell-to-21-3-227fe7ca/)

[All Danaher (DHR) coverage →](https://www.bullished.co/tag/dhr/)